Pharmacokinetic Profile of Tigecycline in Serum and Skin Blister Fluid of Healthy Subjects after Multiple Intravenous Administrations
- 1 April 2005
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (4) , 1629-32
- https://doi.org/10.1128/aac.49.4.1629-1632.2005
Abstract
The pharmacokinetics of tigecycline, when given as a 100-mg loading dose followed by 50 mg every 12 h, were determined in serum and blister fluid. The peak tigecycline concentration and half-life in serum were greater than those in blister fluid. Tigecycline penetrates into blister fluid well, with a mean penetration rate of 74%.Keywords
This publication has 17 references indexed in Scilit:
- Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapyInternational Journal of Antimicrobial Agents, 2003
- Pharmacokinetic Profile of Meropenem, Administered at 500 Milligrams Every 8 Hours, in Plasma and Cantharidin-Induced Skin Blister FluidAntimicrobial Agents and Chemotherapy, 2003
- Production and resolution of cantharidin-induced inflammatory blistersInternational Journal of Antimicrobial Agents, 2003
- Activities of the Glycylcycline Tigecycline (GAR-936) against 1,924 Recent European Clinical Bacterial IsolatesAntimicrobial Agents and Chemotherapy, 2003
- Antimicrobial susceptibility of community-acquired respiratory tract pathogens in North America in 1999-2000: findings of the PROTEKT surveillance studyDiagnostic Microbiology and Infectious Disease, 2002
- Occurrence and antimicrobial susceptibility patterns of pathogens isolated from skin and soft tissue infections: report from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 2000)Diagnostic Microbiology and Infectious Disease, 2002
- In Vitro and In Vivo Activities of Tigecycline (GAR-936), Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-IntermediateStaphylococcus aureusand Other Resistant Gram-Positive PathogensAntimicrobial Agents and Chemotherapy, 2002
- In Vitro Activities of Tigecycline (GAR-936) against Recently Isolated Clinical Bacteria in SpainAntimicrobial Agents and Chemotherapy, 2002
- In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamasesDiagnostic Microbiology and Infectious Disease, 2001
- Antipneumococcal Activities of GAR-936 (a New Glycylcycline) Compared to Those of Nine Other Agents against Penicillin-Susceptible and -Resistant PneumococciAntimicrobial Agents and Chemotherapy, 2000